alexa Aids|OMICS International|Journal Of AIDS And Clinical Research

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Webinars & Conferences

Infectious Diseases and Control

New York, USA

Clinical Research & Clinical Trials

New York, USA

HIV Reactivation

An important benchmark in human immunodeficiency virus (HIV) infection management is the elimination of virus from the infected individual. However, complete viral clearance is not achieved through any of the currently available treatment options. Nonetheless, combined antiretroviral therapy (cART) provides a “functional cure” and decreases viral loads to below detection in blood plasma in many patients. Unfortunately, HIV persists in reservoir sites such as resting T-cells in lymph nodes and microglia/macrophages in the central nervous system (CNS). Potential reactivation of latent virus from these reservoir sites prevents achieving a sterilizing cure Viral reactivation from the resting T-cell population are often described as “blips” in HIV-infected individuals undergoing cART, while routinely maintaining viral loads to below detection levels (HIV RNA>50 copies/mL by standard assays). Such viral resurgence is attributed in part, to immune activation often resulting from onset of opportunistic infections thereby accelerating disease progression.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2020